Clinical-stage regenerative medicine company Cambium Bio (ASX:CMB) has announced that the US FDA has approved the protocol for the registration-enabling Phase 3 clinical trials of Elate Ocular for the treatment of moderate to severe dry eye disease. …
Latest Video
Georgia Forrest
New Stories
-
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News -
Mark Butler steps in to block eye injection funding change after patient warnings
March 10, 2026 - - Latest News -
Pharmac says new agreement has improved access to treatment for New Zealanders
March 10, 2026 - - Latest News -
Island Pharmaceuticals expands antiviral program through Burnet Institute collaboration
March 9, 2026 - -
New cancer research highlights potential of narmafotinib to koost KRAS Inhibitor therapies
March 9, 2026 - - Australian Biotech -
Lateral Pharma secures key U.S. patent for novel neuropathic pain therapy
March 9, 2026 - - Australian Biotech